Hematopoiesis News Volume 14.47 | Nov 28 2023

    0
    14








    2023-11-28 | HN 14.47


    Hematopoiesis News by STEMCELL Technologies
    Vol. 14.47 – 28 November, 2023
    TOP STORY

    Therapeutic Targeting of EP300/CBP by Bromodomain Inhibition in Hematologic Malignancies

    In a subset of patients with relapsed or refractory disease, CCS1477 monotherapy induced differentiation responses in AML and objective responses in heavily pre-treated multiple myeloma.
    [Cancer Cell]

    Full ArticleGraphical Abstract
    Request a free copy of this wallchart on various human HSPC subsets, including their frequencies and phenotypes.
    PUBLICATIONSRanked by the impact factor of the journal

    Platelets Mediate the Clearance of Senescent Red Blood Cells by Forming Pro-Phagocytic Platelet-Cell Complexes

    Pulse-chase labeling studies in mice revealed an approximately ten-fold increase in platelet-red blood cell complexes in the most chronologically aged red blood cell population, compared to younger cells.
    [Blood]

    Abstract

    Base Editing of the HBG Promoter Induces Potent Fetal Hemoglobin Expression with No Detectable Off-Target Mutations in Human HSCs

    The authors used transformer base editor, a recently developed cytosine base editor with no detectable off-target mutations, to disrupt transcription-factor-binding motifs in HSCs.
    [Cell Stem Cell]

    AbstractGraphical AbstractPress Release

    An Alternative NURF Complex Sustains Acute Myeloid Leukemia by Regulating the Accessibility of Insulator Regions

    Using a CRISPRi screen targeting chromatin factors, scientists identified the nucleosome-remodeling factor (NURF) subunit BPTF as an essential regulator of AML cell survival.
    [EMBO Journal]

    Full ArticleGraphical Abstract

    Removal of Innate Immune Barriers Allows Efficient Transduction of Quiescent Human Hematopoietic Stem Cells

    Researchers reported the development of a lentiviral transduction protocol that overcomes thre resistance to genetic manipulation in long-term repopulating quiescent HSC, allowing their efficient genetic manipulation.
    [Molecular Therapy]

    AbstractFull ArticleGraphical Abstract

    Gestational Diabetes in Mice Induces Hematopoietic Memory That Impacts the Long-Term Health of the Offspring

    In mouse models, investigators found that the development of atherosclerosis in adult offspring born to diabetic pregnancy could be in part linked to hematopoietic alterations.
    [JCI Insight]

    AbstractFull ArticleGraphical Abstract

    Association of DDX5/p68 Protein with the Upstream Erythroid Enhancer Element (EHS1) of the Gene Encoding the KLF1 Transcription Factor

    Scientists used biochemical affinity purification to identify the DDX5/p68 protein as an activator of KLF1 by virtue of its interaction with the erythroid-specific DNAse hypersensitive site upstream enhancer element.
    [Journal Of Biological Chemistry]

    Abstract

    Tamoxifen for the Treatment of Myeloproliferative Neoplasms: A Phase II Clinical Trial and Exploratory Analysis

    TAMARIN Phase-II, multicenter, single-arm clinical trial assessed tamoxifen’s safety and activity in patients with stable myeloproliferative neoplasms, no prior thrombotic events and mutated JAK2V617F, CALRins5 or CALRdel52 peripheral blood allele burden ≥20%.
    [Nature Communications]

    Full Article

    A Prospective, Multicenter Study on Hematopoietic Stem-Cell Mobilization with Cyclophosphamide Plus Granulocyte Colony-Stimulating Factor and ‘On-Demand’ Plerixafor in Multiple Myeloma Patients Treated with Novel Agents

    301 patients with a median age 60 years were enrolled. Of them, 287 and 274 patients collected ≥2 and ≥4×106 CD34+ cells/kg, respectively, with a median of 9.9×106 CD34+ cells/kg collected.
    [Haematologica]

    Abstract
    Achieve hassle-free PBMC isolation with SepMateâ„¢
    REVIEWS

    Bidirectional Interplay between Metabolism and Epigenetics in Hematopoietic Stem Cells and Leukemia

    The authors provide an in-depth review of the metabolic and epigenetic interplay regulating hematopoietic stem cell fate, and discuss the influence of metabolic stress stimuli, as well as alterations occurring during leukemic development.
    [EMBO Journal]

    Full Article
    INDUSTRY AND POLICY NEWS

    MorphoSys, after Saying AbbVie ‘Failed,’ Defends Own Mixed Blood Cancer Data, Plots Approval Filings

    The data come from a Phase III clinical trial of pelabresib, a BET inhibitor that MorphoSys acquired in its $1.7 billion acquisition of Constellation Pharmaceuticals.
    [FierceBiotech]

    Editorial
    FEATURED EVENT

    Stem Cells and Regeneration

    January 22 – 25, 2024
    Santa Fe, New Mexico, United States

    > See All Events

    JOB OPPORTUNITIES

    PhD Position – Aging of Human Hematopoietic Stem Cells

    Karolinska Institutet – Flemingsberg, Sweden

    Postdoctoral Associate – Hemostasis and Thromboinflammation in Sickle Cell Disease

    University of Pittsburgh – Pittsburgh, Pennsylvania, United States

    PhD Position – Expanding Blood Stem Cells

    University of York – York, England, United Kingdom

    Postdoctoral Researcher – Haematopoietic Stem Cell Biology

    University of York – York, England, United Kingdom

    Postdoctoral Fellow – Functional Genomics

    Masaryk University – Brno, Czech Republic

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2